MedPath

PharmaJet's Needle-free Delivery System Shows Promise for African Immunization Programs

• PharmaJet's Tropis needle-free delivery system has demonstrated significant benefits in routine immunization programs across multiple African countries, including Nigeria, Somalia, and Pakistan.

• The company will showcase its innovative needle-free intradermal delivery technology at the upcoming Ethiopian Medical Association's 61st Annual Medical Conference in February 2025.

• Clinical evidence from multiple countries supports the effectiveness of PharmaJet's technology, particularly in mass vaccination campaigns and routine immunization programs.

PharmaJet is set to demonstrate the advantages of its innovative needle-free delivery technology at the Ethiopian Medical Association's upcoming medical conference, building on successful implementations across multiple African nations.
The company's Tropis® System, which has received both CE Mark and WHO PQS certification for intradermal injections, has shown remarkable success in various immunization programs. Paul LaBarre, Vice President of Global Business Development at PharmaJet, emphasized the technology's impact: "The Nigeria study results demonstrate how using Tropis for routine immunization programs can provide significant benefits at all levels of the healthcare system."

Clinical Evidence and Implementation Success

Recent evidence from multiple countries has validated the effectiveness of PharmaJet's needle-free delivery system. In Pakistan, research has shown positive acceptance among caregivers and vaccinators for mass administration of fractional dose inactivated poliovirus vaccine (fIPV). Similar successful implementations have been documented in Somalia and Nigeria, particularly in house-to-house vaccination campaigns.

Technology and Regulatory Status

PharmaJet's portfolio includes two key systems:
  • The Stratis® System, which has secured U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification for intramuscular or subcutaneous delivery
  • The Tropis® System, specifically designed for intradermal injections, holding CE Mark and WHO PQS certification

Upcoming Conference Showcase

The technology will be featured at the Ethiopian Medical Association's 61st Annual Medical Conference and International Health Exhibition, scheduled for February 21-22, 2025, in Addis Ababa. The conference is expected to attract over 3,000 international and local healthcare professionals, providing a platform for showcasing advanced medical technologies and facilitating knowledge exchange among healthcare practitioners.
The company is actively pursuing partnerships with the Ethiopian Ministry of Health and other African healthcare organizations to expand the implementation of their needle-free delivery systems in regional immunization programs.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Vaxxas Advances Revolutionary Needle-Free Vaccine Patch in Largest HD-MAP Clinical Trial

Vaxxas has completed enrollment for a groundbreaking clinical trial of their High-Density Microarray Patch (HD-MAP) technology, testing both adjuvanted and adjuvant-free vaccine formulations for enhanced delivery.
Previous clinical studies demonstrated HD-MAP technology achieved comparable immune responses using just one-sixth of traditional vaccine doses, potentially revolutionizing vaccine administration.

Salignostics' Saliva-Based HIV Test Shows 90%+ Accuracy in Ethiopian Clinical Trial

Salignostics has successfully completed a clinical trial in Ethiopia for its innovative saliva-based HIV rapid test, demonstrating over 90% sensitivity and 98% specificity. This non-invasive diagnostic solution aims to revolutionize HIV testing accessibility, particularly in regions with limited healthcare infrastructure.

Axcynsis Therapeutics' AT03-65 Receives FDA IND Clearance for CLDN6-Targeting ADC

Axcynsis Therapeutics received FDA clearance for its IND application for AT03-65, a differentiated CLDN6-targeting antibody-drug conjugate (ADC).
AT03-65 leverages Axcynsis' AxcynDOT™ technology for precise drug delivery to tumors expressing CLDN6, a target in various cancers.

NSW Pharmacy Trials Expand Access to Care for UTIs, Contraceptives, and Skin Conditions

Pharmacy-led trials in NSW, Australia, have successfully expanded healthcare access for uncomplicated UTIs, allowing trained pharmacists to manage and treat the condition.
A trial resupplying oral contraceptives through pharmacies has shown positive feedback, leading to an expansion of patient age eligibility from 18-35 to 18-49 years.

Lilly and EVA Pharma Receive Egyptian Approval for Insulin Injection

The Egyptian Drug Authority has approved Lilly and EVA Pharma's human insulin glargine injection for treating type 1 and type 2 diabetes.
This collaboration aims to provide affordable insulin to at least one million individuals in low to middle-income countries, primarily in Africa, annually.

Belhaven Biopharma to Present Nasdepi(R) Data at DDL 2024

Belhaven Biopharma is set to present new research findings on Nasdepi(R), its innovative dry powder nasal epinephrine product, at the 35th annual Drug Delivery to the Lungs (DDL) Conference. The studies highlight Nasdepi(R)'s effectiveness in real-world patient situations and its ability to withstand high temperatures, offering a needle-free alternative to traditional epinephrine autoinjectors.

Pediatric Trials Network Addresses Critical Gaps in Pediatric Drug Research

The Pediatric Trials Network (PTN) is dedicated to studying the safety, effectiveness, and appropriate dosing of drugs in children.
PTN focuses on off-patent drugs, which are often not tested in pediatric populations due to lack of market exclusivity.

India Updates Drug and Healthcare Regulations, August 2024

The Drugs Controller General of India (DCGI) has waived clinical trial requirements for specific drug categories approved in certain countries.
The CDSCO has mandated manufacturers to comply with revised Schedule M and WHO Technical Report Series guidelines for pharmaceutical products.

Mpox Vaccine Trials Advance with mRNA Candidates and Pediatric Studies

Moderna and BioNTech are in Phase I/II trials for mRNA mpox vaccines, assessing safety and immunogenicity in adults, with Moderna's trial design considered robust.
Bavarian Nordic's Jynneos vaccine is under investigation in a Phase II trial in the Democratic Republic of Congo, focusing on immunogenicity and safety in children aged 2-12.

Doherty Clinical Trials to Conduct Phase I Trial of Needle-Free Avian Influenza Vaccine

Doherty Clinical Trials initiates a Phase I clinical trial for a needle-free avian influenza vaccine developed by Vaxxas, assessing its safety and tolerability.
The trial utilizes Vaxxas' High-Density Microarray Patch (HD-MAP) technology, delivering the vaccine to immune cells just below the skin surface.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy